EP
AXSM icon

Edgestream Partners’s Axsome Therapeutics AXSM Stock Holding History

Edgestream Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13M Buy
+8,718
New +$1.89M 0.06% 501
2026
Q1 		– Sell
-56,364
Closed -$10.3M – 884
2025
Q4 		$10.3M Buy
56,364
+38,018
+207% +$5.31M 0.29% 58
2025
Q3 		$2.23M Sell
18,346
-51,615
-74% -$5.81M 0.07% 500
2025
Q2 		$7.3M Sell
69,961
-125
-0.2% -$13.2K 0.2% 178
2025
Q1 		$8.17M Buy
+70,086
New +$7.98M 0.28% 85

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Edgestream Partners's AXSM Position: Q2 2026 in Review

Edgestream Partners opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 8,718 shares worth $2.13M. The stake represents 0.06% of the portfolio and ranks #501 among its holdings. This is a return to the name: Edgestream Partners previously reported a position in AXSM as recently as Q4 2025.

Edgestream Partners first reported a position in AXSM in Q1 2025 and has held it in 5 quarters since. The position peaked at $10.3M in Q4 2025. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Edgestream Partners held 8,718 shares of Axsome Therapeutics worth $2.13M as of Q2 2026.
  • Axsome Therapeutics was a new Edgestream Partners position in Q2 2026.
  • Axsome Therapeutics made up 0.06% of Edgestream Partners's portfolio in Q2 2026, its #501 holding.
  • Edgestream Partners first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Edgestream Partners's Axsome Therapeutics position peaked at $10.3M in Q4 2025.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.